## Lawrence Eichenfield

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3717130/publications.pdf Version: 2024-02-01

		13865	12946
255	19,178	67	131
papers	citations	h-index	g-index
271	271	271	11315
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. Journal of Allergy and Clinical Immunology, 2010, 126, 1105-1118.	2.9	1,614
2	Guidelines for the Diagnosis and Management of Food Allergy in the United States: Report of the NIAID-Sponsored Expert Panel. Journal of Allergy and Clinical Immunology, 2010, 126, S1-S58.	2.9	1,149
3	Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology, 2014, 71, 116-132.	1.2	970
4	Guidelines of care for the management ofÂatopicÂdermatitis. Journal of the American Academy of Dermatology, 2014, 70, 338-351.	1.2	889
5	Guidelines of care for the management of atopicÂdermatitis. Journal of the American Academy of Dermatology, 2014, 71, 327-349.	1.2	695
6	Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. Journal of the American Academy of Dermatology, 2016, 75, 494-503.e6.	1.2	425
7	Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel. Journal of Allergy and Clinical Immunology, 2017, 139, 29-44.	2.9	374
8	Etanercept Treatment for Children and Adolescents with Plaque Psoriasis. New England Journal of Medicine, 2008, 358, 241-251.	27.0	366
9	Altered proliferation and networks in neural cells derived from idiopathic autistic individuals. Molecular Psychiatry, 2017, 22, 820-835.	7.9	349
10	Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. Journal of the American Academy of Dermatology, 2002, 46, 495-504.	1.2	330
11	A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology, 2001, 44, S47-S57.	1.2	278
12	Baricitinib in patients with moderateâ€toâ€severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase <scp>III</scp> trials. British Journal of Dermatology, 2020, 183, 242-255.	1.5	277
13	Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). Journal of the American Academy of Dermatology, 2018, 78, 863-871.e11.	1.2	267
14	Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology, 2014, 71, 1218-1233.	1.2	256
15	Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 2020, 156, 411.	4.1	241
16	Consensus conference on pediatric atopic dermatitis. Journal of the American Academy of Dermatology, 2003, 49, 1088-1095.	1.2	226
17	A Clinical Study to Evaluate the Efficacy of ELA-Max (4% Liposomal Lidocaine) as Compared With Eutectic Mixture of Local Anesthetics Cream for Pain Reduction of Venipuncture in Children. Pediatrics, 2002, 109, 1093-1099.	2.1	224
18	Guidelines of care for hemangiomas of infancy. Journal of the American Academy of Dermatology, 1997. 37. 631-637.	1.2	220

#	Article	IF	CITATIONS
19	Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 2020, 156, 1333.	4.1	194
20	Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne. Pediatrics, 2013, 131, S163-S186.	2.1	192
21	Atopic Dermatitis and Asthma: Parallels in the Evolution of Treatment. Pediatrics, 2003, 111, 608-616.	2.1	187
22	Ustekinumab in adolescent patients age 12 to 17Âyears with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. Journal of the American Academy of Dermatology, 2015, 73, 594-603.	1.2	187
23	Management of Atopic Dermatitis in the Pediatric Population. Pediatrics, 2008, 122, 812-824.	2.1	176
24	A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology, 2007, 156, 203-221.	1.5	171
25	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of the American Academy of Dermatology, 2017, 77, 623-633.	1.2	170
26	Current guidelines for the evaluation and management of atopic dermatitis: AÂcomparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. Journal of Allergy and Clinical Immunology, 2017, 139, S49-S57.	2.9	165
27	Infantile Hemangiomas: An Update on Pathogenesis and Therapy. Pediatrics, 2013, 131, 99-108.	2.1	162
28	Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants. Journal of Allergy and Clinical Immunology, 2015, 136, 258-261.	2.9	162
29	Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: Results of a multicenter, randomized double-blind, controlled study. Journal of the American Academy of Dermatology, 2007, 57, 791-799.	1.2	161
30	Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. American Journal of Clinical Dermatology, 2018, 19, 821-838.	6.7	159
31	Practical Considerations in Acne Treatment and the Clinical Impact of Topical Combination Therapy. Pediatric Dermatology, 2008, 25, 1-14.	0.9	156
32	The epidemiology of molluscum contagiosum in children. Journal of the American Academy of Dermatology, 2006, 54, 47-54.	1.2	153
33	Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. Journal of the American Academy of Dermatology, 2021, 85, 863-872.	1.2	151
34	Consensus Guidelines for the Management of Plaque Psoriasis. Archives of Dermatology, 2012, 148, 95.	1.4	148
35	Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1519-1531.	3.8	141
36	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. Journal of the American Academy of Dermatology, 2017, 76, 290-298.	1.2	137

#	Article	IF	CITATIONS
37	Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. British Journal of Dermatology, 2004, 150, 96-102.	1.5	136
38	Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. American Journal of Clinical Dermatology, 2019, 20, 443-456.	6.7	130
39	Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. Journal of the American Academy of Dermatology, 2005, 53, S186-S194.	1.2	125
40	Management of Acne Vulgaris. JAMA - Journal of the American Medical Association, 2021, 326, 2055.	7.4	116
41	Genetic Heterogeneity in Erythrokeratodermia Variabilis: Novel Mutations in the Connexin Gene GJB4 (Cx30.3) and Genotype-Phenotype Correlations. Journal of Investigative Dermatology, 2003, 120, 601-609.	0.7	112
42	Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Human Molecular Genetics, 2014, 23, 397-407.	2.9	112
43	Dupilumab in adolescents with uncontrolled moderateâ€toâ€severe atopic dermatitis: results from a phase <scp>II</scp> a openâ€label trial and subsequent phase <scp>III</scp> openâ€label extension. British Journal of Dermatology, 2020, 182, 85-96.	1.5	111
44	Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology, 2017, 77, 641-649.e5.	1.2	110
45	Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. Journal of the American Academy of Dermatology, 2002, 47, 562-570.	1.2	108
46	Study of the Atopic March: Development of Atopic Comorbidities. Pediatric Dermatology, 2016, 33, 388-398.	0.9	99
47	A Prospective Comparison of Octyl Cyanoacrylate Tissue Adhesive (Dermabond) and Suture for the Closure of Excisional Wounds in Children and Adolescents. Archives of Dermatology, 2001, 137, 1177-80.	1.4	98
48	Long-term etanercept in pediatric patients with plaque psoriasis. Journal of the American Academy of Dermatology, 2010, 63, 762-768.	1.2	96
49	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2018, 178, e332-e341.	1.5	96
50	Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). British Journal of Dermatology, 2014, 171, 1318-1325.	1.5	95
51	Isotretinoin and Timing of Procedural Interventions. JAMA Dermatology, 2017, 153, 802.	4.1	93
52	OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. Journal of the American Academy of Dermatology, 2016, 75, 297-305.	1.2	88
53	Emerging therapies for atopic dermatitis: JAK inhibitors. Journal of the American Academy of Dermatology, 2018, 78, S53-S62.	1.2	88
54	Pulmonary Thromboembolism Associated With Klippel-Trenaunay Syndrome. Pediatrics, 2005, 116, e596-e600.	2.1	87

#	Article	IF	CITATIONS
55	Pediatric Psoriasis Comorbidity Screening Guidelines. JAMA Dermatology, 2017, 153, 698.	4.1	84
56	Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis. JAMA Dermatology, 2021, 157, 1165.	4.1	79
57	Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care Providers. Pediatrics, 2015, 136, 554-565.	2.1	78
58	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. Journal of the American Academy of Dermatology, 2020, 83, 839-846.	1.2	78
59	Periorificial dermatitis in children and adolescents. Journal of the American Academy of Dermatology, 2006, 55, 781-785.	1.2	77
60	Contact sensitization in very young children. Journal of the American Academy of Dermatology, 2011, 65, 772-779.	1.2	75
61	Therapeutic Patient Education in Atopic Dermatitis: Worldwide Experiences. Pediatric Dermatology, 2013, 30, 329-334.	0.9	75
62	MAS063DP is Effective Monotherapy for Mild to Moderate Atopic Dermatitis in Infants and Children: A Multicenter, Randomized, Vehicle-Controlled Study. Journal of Pediatrics, 2008, 152, 854-859.	1.8	74
63	Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. Journal of the American Academy of Dermatology, 2017, 76, 281-285.	1.2	73
64	Three Times Weekly Tacrolimus Ointment Reduces Relapse in Stabilized Atopic Dermatitis: A New Paradigm for Use. Pediatrics, 2008, 122, e1210-e1218.	2.1	72
65	Quantitative Assessment of Combination Bathing and Moisturizing Regimens on Skin Hydration in Atopic Dermatitis. Pediatric Dermatology, 2009, 26, 273-278.	0.9	72
66	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatric Allergy and Immunology, 2015, 26, 306-315.	2.6	71
67	Female infant with oncocytic cardiomyopathy and microphthalmia with linear skin defects (MLS): A clue to the pathogenesis of oncocytic cardiomyopathy?. American Journal of Medical Genetics Part A, 1994, 53, 141-148.	2.4	69
68	Validating outdoor workers' self-report of sun protection. Preventive Medicine, 2004, 39, 798-803.	3.4	69
69	Compliance with federal and state legislation by indoor tanning facilities in San Diego. Journal of the American Academy of Dermatology, 2001, 44, 53-60.	1.2	67
70	Current management of atopic dermatitis and interruption of the atopic march. Journal of Allergy and Clinical Immunology, 2003, 112, S140-S150.	2.9	67
71	Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. Journal of the American Academy of Dermatology, 2011, 64, 175-192.	1.2	67
72	Consensus Conference on Clinical Management of pediatric Atopic Dermatitis. Italian Journal of Pediatrics, 2016, 42, 26.	2.6	67

#	Article	IF	CITATIONS
73	Pediatric psoriasis: Evolving perspectives. Pediatric Dermatology, 2018, 35, 170-181.	0.9	66
74	Cutaneous telangiectases in neonatal lupus erythematosus. Journal of the American Academy of Dermatology, 1995, 33, 19-25.	1.2	65
75	Evidence-based recommendations for the management of acne fulminans and its variants. Journal of the American Academy of Dermatology, 2017, 77, 109-117.	1.2	64
76	Elidel (pimecrolimus) cream 1%: A nonsteroidal topical agent for the treatment of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2003, 111, 1153-1168.	2.9	62
77	Atopic Dermatitis: Epidemiology and Pathogenesis Update. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S3-S5.	1.6	60
78	Therapeutic Patient Education in Children with Atopic Dermatitis: Position Paper on Objectives and Recommendations. Pediatric Dermatology, 2013, 30, 199-206.	0.9	60
79	Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel. Annals of Allergy, Asthma and Immunology, 2017, 118, 166-173.e7.	1.0	59
80	Atopic dermatitis: pathogenesis. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 100-103.	1.6	59
81	Pediatric "STUMP―lesions: Evaluation and management of difficult atypical Spitzoid lesions in children. Journal of the American Academy of Dermatology, 2011, 64, 559-572.	1.2	58
82	Understanding and Managing Atopic Dermatitis in Adult Patients. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S18-S22.	1.6	57
83	The Benefits of Sunflower Oleodistillate (SOD) in Pediatric Dermatology. Pediatric Dermatology, 2009, 26, 669-675.	0.9	56
84	Food Allergy in Infants With Atopic Dermatitis: Limitations of Food-Specific IgE Measurements. Pediatrics, 2015, 136, e1530-e1538.	2.1	55
85	The impact of airborne pollution on atopic dermatitis: a literature review. British Journal of Dermatology, 2020, 183, 16-23.	1.5	54
86	American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults. Journal of the American Academy of Dermatology, 2022, 86, 1335-1336.e18.	1.2	54
87	Acne Epidemiology and Pathophysiology. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 2-4.	1.6	53
88	Ustekinumab for the treatment of moderateâ€toâ€severe plaque psoriasis in paediatric patients (≥ 6 to <) <scp>CADMUS</scp> Jr study. British Journal of Dermatology, 2020, 183, 664-672.	Tj ETQq0 1.5	0 0 rgBT /Ove 53
89	Acne and Rosacea. Dermatology and Therapy, 2017, 7, 43-52.	3.0	52
90	Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the <scp>TOPICOP</scp> score. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1713-1719.	5.7	52

#	Article	IF	CITATIONS
91	Use of the Cotton Swab Method in Diagnosing Tinea Capitis. Pediatrics, 1999, 104, 276-279.	2.1	51
92	Pediatric Anesthesia in Dermatologic Surgery: When Hand-Holding is Not Enough. Dermatologic Surgery, 2001, 27, 1010-1018.	0.8	50
93	Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. Journal of the American Academy of Dermatology, 2004, 51, 709-717.	1.2	50
94	Congenital localized scleroderma. Journal of Pediatrics, 2006, 149, 248-251.	1.8	50
95	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1224-1231.	2.4	50
96	Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel. World Allergy Organization Journal, 2017, 10, 1.	3.5	48
97	VASCULAR AND PIGMENTED BIRTHMARKS. Pediatric Clinics of North America, 2000, 47, 783-812.	1.8	47
98	A Practical Approach for the Use of Oral Isotretinoin for Infantile Acne. Pediatric Dermatology, 2005, 22, 166-169.	0.9	46
99	Children with Atopic Dermatitis Appear Less Likely to Be Infected with Community Acquired Methicillinâ€Resistant <i>Staphylococcus aureus</i> : The San Diego Experience. Pediatric Dermatology, 2011, 28, 6-11.	0.9	46
100	Longâ€ŧerm safety and efficacy of trifarotene 50Âμg/g cream, a firstâ€inâ€class <scp>RAR</scp> â€Î³ selective topical retinoid, in patients with moderate facial and truncal acne. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 166-173.	2.4	46
101	Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. Journal of Drugs in Dermatology, 2007, 6, 607-15.	0.8	46
102	Analyzing the Genetic Spectrum of Vascular Anomalies with Overgrowth viaÂCancer Genomics. Journal of Investigative Dermatology, 2018, 138, 957-967.	0.7	45
103	Dupilumab provides favourable longâ€ŧerm safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an openâ€label phase IIa study and subsequent phase III openâ€label extension study. British Journal of Dermatology, 2021, 184, 857-870.	1.5	45
104	The Safety and Efficacy of Tacrolimus Ointment in Pediatric Patients with Atopic Dermatitis. Pediatric Dermatology, 2010, 27, 425-436.	0.9	44
105	Identifying Potential Regulators of Infantile Hemangioma Progression through Large-scale Expression Analysis: A Possible Role for the Immune System and Indoleamine 2,3 Dioxygenase (IDO) during Involution. Lymphatic Research and Biology, 2003, 1, 291-299.	1.1	43
106	Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a splitâ€body randomized controlled trial. British Journal of Dermatology, 2016, 175, 212-214.	1.5	43
107	Intermittent etanercept therapy in pediatric patients with psoriasis. Journal of the American Academy of Dermatology, 2010, 63, 769-774.	1.2	42
108	Atopic Dermatitis Pediatrics in Review 2018 39 180-193	0.4	49

Atopic Dermatitis. Pediatrics in Review, 2018, 39, 180-193. 108

0.4 42

#	Article	IF	CITATIONS
109	Promoting Sun Safety among Zoo Visitors. Preventive Medicine, 2001, 33, 162-169.	3.4	41
110	Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Reveals a More Atherogenic Profile. Journal of Investigative Dermatology, 2016, 136, 67-73.	0.7	38
111	Update on Epidemiology, Diagnosis, and Disease Course of Atopic Dermatitis. Seminars in Cutaneous Medicine and Surgery, 2016, 35, S84-S88.	1.6	38
112	Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis, 2010, 85, 94-104.	0.3	38
113	Consensus recommendations from the American acne & rosacea society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis, 2014, 93, 71-6.	0.3	38
114	Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis. Journal of Patient-Reported Outcomes, 2019, 3, 42.	1.9	36
115	Hidradenitis Suppurativa in the Pediatric Population. JAMA Dermatology, 2021, 157, 385.	4.1	36
116	Fluocinolone acetonide 0.01% in peanut oil: Therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. Journal of the American Academy of Dermatology, 2003, 48, 569-577.	1.2	35
117	Diaper dermatitis prevalence and severity: Global perspective on the impact of caregiver behavior. Pediatric Dermatology, 2020, 37, 130-136.	0.9	34
118	Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. Pediatric Dermatology, 2021, 38, 164-180.	0.9	34
119	Atopic Dermatitis. Dermatologic Clinics, 2019, 37, 11-20.	1.7	33
120	Effect of Desonide Hydrogel 0.05% on the Hypothalamic-Pituitary-Adrenal Axis in Pediatric Subjects with Moderate to Severe Atopic Dermatitis. Pediatric Dermatology, 2007, 24, 289-295.	0.9	32
121	Photodynamic therapy with methyl aminolaevulinate 80 mg gâ^ 1for severe facial acne vulgaris: a randomized vehicle-controlled study. British Journal of Dermatology, 2016, 174, 770-777.	1.5	32
122	Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook. Drugs, 2017, 77, 1389-1397.	10.9	31
123	Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome. JAMA Dermatology, 2021, 157, 98.	4.1	31
124	Clinical Management of Atopic Eczema with Pimecrolimus Cream 1% (Elidel®) in Paediatric Patients. Dermatology, 2007, 215, 3-17.	2.1	30
125	A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patientâ€Education Network in Dermatology (OPENED) task force. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 787-796.	2.4	30
126	<scp>TRE</scp> atment of <scp>AT</scp> opic eczema ( <scp>TREAT</scp> ) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. British Journal of Dermatology, 2019, 181, 492-504.	1.5	29

#	Article	IF	CITATIONS
127	The Acne Continuum: An Age-Based Approach to Therapy. Seminars in Cutaneous Medicine and Surgery, 2011, 30, S6-S11.	1.6	28
128	Optimizing outcomes for paediatric atopic dermatitis. British Journal of Dermatology, 2014, 170, 31-37.	1.5	27
129	Epidemiologic Analysis of Onychomycosis in the San Diego Pediatric Population. Pediatric Dermatology, 2017, 34, 46-49.	0.9	27
130	Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America. JAMA Dermatology, 2019, 155, 196.	4.1	27
131	Effect of cat and daycare exposures on the risk of asthma in children with atopic dermatitis. Allergy and Asthma Proceedings, 2012, 33, 282-288.	2.2	26
132	<scp>TRE</scp> atment of <scp>AT</scp> opic eczema ( <scp>TREAT</scp> ) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo―and systemic therapy registries. British Journal of Dermatology, 2019, 180, 790-801.	1.5	26
133	Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1305-1313.	2.4	24
134	Use of dupilimab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis. Pediatric Dermatology, 2019, 36, 172-176.	0.9	24
135	Cranial Fasciitis of Childhood. Pediatric Dermatology, 1999, 16, 232-234.	0.9	23
136	Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-risk Infants. Pediatrics, 2015, 136, 600-604.	2.1	23
137	Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. Journal of the American Academy of Dermatology, 2020, 83, 477-485.	1.2	23
138	Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study. Journal of Drugs in Dermatology, 2011, 10, 1382-96.	0.8	23
139	Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database. Dermatology and Therapy, 2020, 10, 791-806.	3.0	22
140	Current and emerging topical therapies for atopic dermatitis. Clinics in Dermatology, 2017, 35, 375-382.	1.6	21
141	Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults. Journal of Pediatrics, 2019, 211, 152-158.	1.8	21
142	Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. Journal of the American Academy of Dermatology, 2006, 54, 715-717.	1.2	20
143	A Novel Gel Formulation of 0.25% Tretinoin and 1.2% Clindamycin Phosphate: Efficacy in Acne Vulgaris Patients Aged 12 to 18 Years. Pediatric Dermatology, 2009, 26, 257-261.	0.9	20
144	Effective monitoring of isotretinoin safety in a pediatric dermatology population: AÂnovel "patient symptom survey―approach. Journal of the American Academy of Dermatology, 2011, 65, 517-524.	1.2	20

#	Article	IF	CITATIONS
145	Safety and Efficacy of Calcipotriene Plus Betamethasone Dipropionate Topical Suspension in the Treatment of Extensive Scalp Psoriasis in Adolescents Ages 12 to 17 Years. Pediatric Dermatology, 2015, 32, 28-35.	0.9	20
146	Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–Sponsored Expert Panel. Pediatric Dermatology, 2017, 34, e1-e21.	0.9	20
147	Current Issues in Atopic Comorbidities and Preventing the Atopic March. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S6-S9.	1.6	19
148	Phenotypic spectrum of autosomal recessive congenital ichthyosis due to <i>PNPLA1</i> mutation. British Journal of Dermatology, 2017, 177, 319-322.	1.5	19
149	Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum. JAMA Dermatology, 2020, 156, 1315.	4.1	19
150	Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. Journal of Dermatology, 2007, 34, 231-236.	1.2	18
151	Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families. Dermatology and Therapy, 2018, 8, 605-619.	3.0	18
152	Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. Journal of Drugs in Dermatology, 2010, 9, 33-40.	0.8	18
153	Study of the Efficacy and Tolerability of 0.04% Tretinoin Microsphere Gel for Preadolescent Acne. Pediatrics, 2010, 125, e1316-e1323.	2.1	17
154	Addendum guidelines for the prevention of peanut allergy in the United States. Pediatric Dermatology, 2017, 34, 5-12.	0.9	17
155	The microbiome in preadolescent acne: Assessment and prospective analysis of the influence of benzoyl peroxide. Pediatric Dermatology, 2019, 36, 200-206.	0.9	17
156	Characterization of wound microbes in epidermolysis bullosa: Results from the epidermolysis bullosa clinical characterization and outcomes database. Pediatric Dermatology, 2021, 38, 119-124.	0.9	17
157	Emerging Issues in Adult Female Acne. Journal of Clinical and Aesthetic Dermatology, 2017, 10, 37-46.	0.1	17
158	Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides. Journal of Drugs in Dermatology, 2013, 12, 611-8.	0.8	17
159	Treatment of ichthyosiform diseases with topically applied tazarotene: Risk of systemicÂabsorption. Journal of the American Academy of Dermatology, 2007, 57, S123-S125.	1.2	16
160	Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry. Pediatric Dermatology, 2018, 35, 303-322.	0.9	16
161	Management of Severe Atopic Dermatitis in Pediatric Patients. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1462-1471.	3.8	16
162	Atopic dermatitis: therapeutic care delivery: therapeutic education, shared decision-making, and access to care. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 131-136.	1.6	16

#	Article	IF	CITATIONS
163	Pediatric acne: clinical presentations, evaluation, and management. Journal of Drugs in Dermatology, 2007, 6, 589-93.	0.8	16
164	Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting. Paediatric Drugs, 2022, 24, 293-305.	3.1	16
165	Fluocinolone Acetonide 0.01% in Peanut Oil: Safety and Efficacy Data in the Treatment of Childhood Atopic Dermatitis in Infants as Young as 3 Months of Age. Pediatric Dermatology, 2009, 26, 262-268.	0.9	15
166	Topical therapy of atopic dermatitis with a focus on pimecrolimus. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1505-1518.	2.4	15
167	Natural advances in eczema care. Cutis, 2007, 80, 2-16.	0.3	15
168	Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–Sponsored Expert Panel. Journal of Pediatric Nursing, 2017, 32, 91-98.	1.5	14
169	TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. British Journal of Dermatology, 2020, 182, 1423-1429.	1.5	14
170	Assessing the New and Emerging Treatments for Atopic Dermatitis. Seminars in Cutaneous Medicine and Surgery, 2016, 35, S92-S96.	1.6	14
171	Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use. Iournal of Clinical and Aesthetic Dermatology. 2016. 9. 18-24.	0.1	14
172	Vesiculopustular Eruption of Crohn's Disease. Pediatric Dermatology, 1996, 13, 127-130.	0.9	13
173	An Update on Pediatric Atopic Dermatitis and Food Allergies. Journal of Pediatrics, 2015, 167, 752-756.	1.8	13
174	Phase 4 study to assess tretinoin pump for the treatment of facial acne. Journal of Drugs in Dermatology, 2008, 7, 1129-36.	0.8	13
175	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADâ,,¢): a clinical outcome measure for the severity of atopic dermatitis. British Journal of Dermatology, 2022, 187, 531-538.	1.5	13
176	Disseminated linear calcinosis cutis associated with the Koebner phenomenon in an infant with congenital acute monocytic leukaemia. British Journal of Dermatology, 2004, 150, 753-756.	1.5	12
177	Novel tretinoin 0.05% lotion for the onceâ€daily treatment of moderateâ€ŧoâ€severe acne vulgaris in a preadolescent population. Pediatric Dermatology, 2019, 36, 193-199.	0.9	12
178	Long-term safety of tacrolimus ointment in children treated for atopic dermatitis. Expert Opinion on Drug Safety, 2003, 2, 457-465.	2.4	11
179	Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. Allergy, Asthma and Clinical Immunology, 2017, 13, .	2.0	11
180	Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensusâ€based guidance for clinical decisionâ€making during the COVIDâ€19 pandemic. Pediatric Dermatology, 2020, 37, 424-434.	0.9	11

#	Article	IF	CITATIONS
181	Absorption and efficacy of miconazole nitrate 0.25% ointment in infants with diaper dermatitis. Journal of Drugs in Dermatology, 2007, 6, 522-6.	0.8	11
182	Pediatric Onychomycosis: The Emerging Role of Topical Therapy. Journal of Drugs in Dermatology, 2017, 16, 105-109.	0.8	11
183	Evaluation of Adrenal Suppression of a Lipid Enhanced, Topical Emollient Cream Formulation of Hydrocortisone Butyrate 0.1% in Treating Children with Atopic Dermatitis. Pediatric Dermatology, 2007, 24, 81-84.	0.9	10
184	Tretinoin Microsphere Gel 0.04% Pump for Treating Acne Vulgaris in Preadolescents: A Randomized, Controlled Study. Pediatric Dermatology, 2012, 29, 598-604.	0.9	10
185	The Benefits of New Guidelines to Prevent Peanut Allergy. Pediatrics, 2017, 139, e20164293.	2.1	10
186	Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study. British Journal of Dermatology, 2019, 180, 1050-1057.	1.5	10
187	Blistering severe cutaneous adverse reactions in children: proposal for paediatricâ€focused clinical criteria. British Journal of Dermatology, 2021, 185, 447-449.	1.5	10
188	Review of Critical Issues in the Pathogenesis of Atopic Dermatitis. Seminars in Cutaneous Medicine and Surgery, 2016, 35, S89-91.	1.6	10
189	Acne and your pediatric patient: a roundtable discussion of treatment modalities and other factors. Cutis, 2005, 76, 5-24.	0.3	10
190	Perspectives on Therapeutic Options for Acne: An Update. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 13-16.	1.6	9
191	The Utility of Cantharidin for the Treatment of Molluscum Contagiosum. Pediatric Dermatology, 2015, 32, 295-295.	0.9	9
192	Skin cleansing and topical product use in patients with epidermolysis bullosa: Results from a multicenter database. Pediatric Dermatology, 2020, 37, 326-332.	0.9	9
193	Update on Pediatric Atopic Dermatitis. , 2020, 106, 143-146.		9
194	Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 3: Current Perspectives on Skin and Soft Tissue Infections with Emphasis on Methicillin-resistant Staphylococcus aureus, Commonly Encountered Scenarios when Antibiotic Use May Not Be Needed, and Concluding Remarks on Rational Use of Antibiotics in Dermatology. Journal of	0.1	9
195	Clinical and Aesthetic Dermatology, 2016, 9, 17-24. Current guidelines for the evaluation and management of atopic dermatitis – A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology Guidelines. Alergologia Polska - Polish Journal of Allergology, 2017, 4, 158-168.	0.0	8
196	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open, 2020, 10, e039928.	1.9	8
197	Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study. Journal of the American Academy of Dermatology, 2021, 84, 1140-1142.	1.2	8
198	Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council. JAAD International, 2021, 3, 8-13.	2.2	8

#	Article	IF	CITATIONS
199	Practical Strategies for the Diagnosis and Assessment of Atopic Dermatitis. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S36-S38.	1.6	8
200	Atopic dermatitis: skin care and topical therapies. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 104-110.	1.6	8
201	Approach to Pediatric Acne Treatment: An Update. Seminars in Cutaneous Medicine and Surgery, 2011, 30, S16-S21.	1.6	7
202	Debates in allergy medicine: Specific immunotherapy in children with atopic dermatitis, the "con―view. World Allergy Organization Journal, 2016, 9, 16.	3.5	7
203	Recurrent herpes labialis in the pediatric population: Prevalence, therapeutic studies, and associated complications. Pediatric Dermatology, 2019, 36, 808-814.	0.9	7
204	Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic—Consensus: Recommendations by an international panel of experts. Journal of the American Academy of Dermatology, 2020, 83, 1222-1224.	1.2	7
205	Addressing the Immunopathogenesis of Atopic Dermatitis: Advances in Topical and Systemic Treatment. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S45-S48.	1.6	7
206	Atopic dermatitis: emerging therapies. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 124-130.	1.6	7
207	Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP). Italian Journal of Pediatrics, 2022, 48.	2.6	7
208	Medical algorithm: Diagnosis of atopic dermatitis in early childhood (part I). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 403-406.	5.7	6
209	Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy. Journal of Dermatological Treatment, 2022, 33, 2057-2062.	2.2	6
210	Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology, 2012, 11, 818-24.	0.8	6
211	Status report from the American Acne & Rosacea Society on medical management of acne in adult women, part 3: oral therapies. Cutis, 2015, 96, 376-82.	0.3	6
212	Atopic dermatitisReview of comorbidities and therapeutics. Annals of Allergy, Asthma and Immunology, 2022, 129, 142-149.	1.0	6
213	Subcutaneous Infusion Anesthesia for Dermatologic Surgery in Children: Are We Ready?. Pediatric Dermatology, 2001, 18, 532-533.	0.9	5
214	Atopic dermatitis: Kids are not just little people. Clinics in Dermatology, 2015, 33, 594-604.	1.6	5
215	Primary cutaneous aspergillosis at the site of cyanoacrylate skin adhesive in a neonate. Pediatric Dermatology, 2018, 35, 494-497.	0.9	5
216	Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mildâ€ŧoâ€moderate atopic dermatitis. Pediatric Dermatology, 2020, 37, 1030-1037.	0.9	5

#	Article	IF	CITATIONS
217	Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. American Journal of Clinical Dermatology, 2021, 22, 257-265.	6.7	5
218	Status report from the American Acne & Rosacea Society on medical management of acne in adult women, part 2: topical therapies. Cutis, 2015, 96, 321-5.	0.3	5
219	Profile of clindamycin phosphate 1.2%/benzoyl peroxide 3.75% aqueous gel for the treatment of acne vulgaris. Clinical, Cosmetic and Investigational Dermatology, 2015, 8, 549.	1.8	4
220	"EB, or Not <scp>EB</scp> ?―Neonatal Desquamative Impetigo in a Degloving Pattern. Pediatric Dermatology, 2016, 33, e147-8.	0.9	4
221	Filling in Pediatric Acne Practice Gaps: A Prospective Multicenter Study of Case-Based Education. Journal of Adolescent Health, 2016, 59, 549-554.	2.5	4
222	Optimizing Clinical Trials for Atopic Dermatitis in Children. Journal of Investigative Dermatology, 2017, 137, 1363-1364.	0.7	4
223	Medical algorithm: Treatment of atopic dermatitis in early childhood (part II). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 407-410.	5.7	4
224	The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement. Journal of Dermatological Treatment, 2022, 33, 2397-2399.	2.2	4
225	Recent advances in understanding and preventing peanut and tree nut hypersensitivity. F1000Research, 2018, 7, 1716.	1.6	4
226	Adolescent Scalp Psoriasis: Update on Topical Combination Therapy. Journal of Clinical and Aesthetic Dermatology, 2015, 8, 43-7.	0.1	4
227	Status report from the American Acne & Rosacea Society on medical management of acne in adult women, part 1: overview, clinical characteristics, and laboratory evaluation. Cutis, 2015, 96, 236-41.	0.3	4
228	A national survey of sun safety activities at U.S. zoos. Journal of Community Health, 2000, 25, 331-342.	3.8	3
229	Diagnosis and Evaluation of Acne. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 5-8.	1.6	3
230	A 6-Day-Old Male Infant With Linear Band of Skin-Colored Papules. JAMA Pediatrics, 2014, 168, 859.	6.2	3
231	Safety and efficacy of topical, fixedâ€dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1098-1104.	2.4	3
232	A retrospective analysis of diagnostic testing in a large North American cohort of patients with epidermolysis bullosa. Journal of the American Academy of Dermatology, 2021, , .	1.2	3
233	Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Pooled Analyses from Two Phase III Randomized Trials Journal of Clinical and Aesthetic Dermatology, 2021, 14, 42-47.	0.1	3
234	Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset. Dermatology and Therapy, 2022, 12, 1337-1350.	3.0	3

#	Article	IF	CITATIONS
235	Religious Allergic Contact Dermatitis. Pediatric Dermatology, 2015, 32, e191-2.	0.9	2
236	Transforming acne care by pediatricians: An interventional cohort study. Journal of the American Academy of Dermatology, 2018, 79, 966-968.	1.2	2
237	Isotretinoin does not contribute to increased neuropsychiatric risk in the overall acne population, but risk management during treatment remains essential. British Journal of Dermatology, 2022, , .	1.5	2
238	Evolving management of atopic dermatitis. Expert Review of Dermatology, 2006, 1, 31-41.	0.3	1
239	Acne in children. , 2011, , 182-197.		1
240	Atypical Caféâ€au‣ait Macules in a Patient with Koolenâ€de Vries Syndrome (17q21.31 Microdeletion) Tj ET	⁻Qq0000r	gBT /Overloc
241	Isotretinoin and iPledge Program patient information video: A new modality that improves patient comprehension. Journal of the American Academy of Dermatology, 2021, 84, 1425-1426.	1.2	1
242	Characteristics of nonmelanoma skin cancer in children without identifiable risk factors. Journal of the American Academy of Dermatology, 2021, 84, 1472-1476.	1.2	1
243	Executive summary: Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. Journal of the American Academy of Dermatology, 2022, 86, 158-161.	1.2	1
244	Atopic Dermatitis Progression: Evaluating Intervention Strategies. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S39-S41.	1.6	1
245	Nonpharmacologic Strategies and Topical Agents for Treating Atopic Dermatitis: An Update. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S42-S44.	1.6	1

246	Curriculum United for Better Eczema Care: why, how, and what?. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 93-94.	1.6	1
247	Unique approaches for the topical treatment and prevention of cutaneous infections: report from a clinical roundtable. Cutis, 2004, 74, 2-23.	0.3	1
248	Introduction. Seminars in Cutaneous Medicine and Surgery, 2011, 30, S1.	1.6	0
249	Perspectives in Atopic Dermatitis-Optimizing Outcomes: Introduction. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S1-S2.	1.6	0
250	High-dose isotretinoin: Bigger dents in wallets?. Journal of the American Academy of Dermatology, 2016, 75, e75-e76.	1.2	0
251	Ocular Manifestations of Dermatologic Diseases. , 2017, , 197-239.		0

Meeting the Challenge of Atopic Dermatitis From Infancy to Adulthood. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S35-S35.

1.6 0

#	Article	IF	CITATIONS
253	Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology SeminarTM. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S52-S59.	1.6	Ο
254	Laser treatment of vascular lesions in children: biologic/laser interactions. , 0, , .		0
255	Not COVID Toes: Pool Palms and Feet in Pediatric Patients. , 2021, 108, 276-295.		0